Investigational antibody-drug conjugates for hematological malignancies

Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy

(2010) Michinori Ogura et al.   CANCER SCIENCE

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

(2010) Anjali Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

(2010) A G Polson et al.   LEUKEMIA

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas

(2009) H.-P. Gerber et al.   BLOOD

Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma

(2009) D. Dornan et al.   BLOOD

P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients

(2009) Ruoping Tang et al.   BMC CANCER

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection

(2009) A. G. Polson et al.   CANCER RESEARCH

Toward an Effective Targeted Chemotherapy for Multiple Myeloma

(2009) A. G. Polson et al.   CLINICAL CANCER RESEARCH

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2009) H. Ikeda et al.   CLINICAL CANCER RESEARCH

Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma

(2009) A. M. Al-Katib et al.   CLINICAL CANCER RESEARCH

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates

(2009) B. Zheng et al.   MOLECULAR CANCER THERAPEUTICS

Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates

(2008) Stephen C. Alley et al.   BIOCONJUGATE CHEMISTRY

Antibody-Drug Conjugates for Cancer Therapy

(2008) Paul J. Carter et al.   CANCER JOURNAL

Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker

(2008) E. Oflazoglu et al.   CLINICAL CANCER RESEARCH

SGN-30: a basis for the effective treatment of CD30 positive hematopoietic malignancies

(2008) Lauren C Pinter-Brown   EXPERT OPINION ON INVESTIGATIONAL DRUGS